Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize

• Published in: Nature communications Vol. 7; no. 1; p. 13019
• Main Authors: Adams, Stephen R., Yang, Howard C., Savariar, Elamprakash N., Aguilera, Joe, Crisp, Jessica L., Jones, Karra A., Whitney, Michael A., Lippman, Scott M., Cohen, Ezra E. W., Tsien, Roger Y., Advani, Sunil J.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 04.10.2016; Nature Publishing Group; Nature Portfolio
• Subjects: 13/1; 13/106; 13/31; 14/19; 14/34; 631/154/309/152; 631/67/1059/485; 64/60; 692/4028/67/1059/602; 82/51; Antibodies; Cancer therapies; Cell cycle; Chemotherapy; Clinical outcomes; Cytotoxicity; Drug dosages; Humanities and Social Sciences; multidisciplinary; Radiation therapy; Science; Science (multidisciplinary); Tumors; La Jolla California; United States > US; California

Tumour resistance to radiotherapy remains a barrier to improving cancer patient outcomes. To overcome radioresistance, certain drugs have been found to sensitize cells to ionizing radiation (IR). In theory, more potent radiosensitizing drugs should increase tumour kill and improve patient outcomes....